Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection-Reference-Cited by-同舟云学术

Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection

Published:2020-10 Issue:11 Volume:18 Page:2544-2553.e6
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Zuckerman Eli,Gutierrez Julio A.,Dylla Douglas E.,de Ledinghen Victor,Muir Andrew J.^ORCID,Gschwantler Michael,Puoti Massimo,Caruntu Florin,Slim Jihad,Nevens Frederik,Sigal Samuel^ORCID,Cohen Stanley,Fredrick Linda M.,Pires dos Santos Ana Gabriela,Rodrigues Lino,Dillon John F.^ORCID

Funder

AbbVie

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference30 articles.

1. EASL recommendations on treatment of hepatitis C 2018;Pawlotsky;J Hepatol,2018

2. Direct-acting antivirals and chronic hepatitis C: towards elimination;Franco;Hepatoma Res,2018

3. Approaches and considerations for the successful treatment of HCV infection. Chapter 16;Smolić,2017

4. Change in demographics of direct-acting antiviral (DAA)-prescribed HCV patients from 2013 to 2018: data from 19,994 patients in the TRIO network (abstract 613);Tsai;Hepatology,2018

5. Changing demographics among populations prescribed HCV treatment, 2013-2017;Tsai;Am J Manag Care,2019

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Perfil clínico de los pacientes españoles con hepatitis C naïve con cirrosis compensada tratados en el estudio CREST;Gastroenterología y Hepatología;2024-06

2. Clinical profile of Spanish hepatitis C virus-infected treatment-naïve patients with compensated cirrhosis in the CREST study;Gastroenterología y Hepatología (English Edition);2024-06

3. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan;Infectious Diseases and Therapy;2024-04-28

4. Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks;2024-04-10

5. Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example;Infectious Diseases and Therapy;2024-03